Try a new search

Format these results:

Searched for:

in-biosketch:true

person:montgr01

Total Results:

520


Swine Xenografts Share Few Predicted Indirectly Recognisable SLA-Derived Epitopes With HLA-Derived Epitopes From Human Kidney Grafts

Matern, Benedict M; Spierings, Eric; Peereboom, Emma; Tector, Matt; Tector, Joseph; Mangiola, Massimo; Montgomery, Robert A; Niemann, Matthias
Swine-derived kidneys are a promising alternative organ source for transplantation, but compatibility in the major histocompatibility complex remains an immunological barrier. Furthermore, in repeat transplantations, CD4+ memory T cells can lead to a more rapid immune response against repeated exposure to the same antigens. Several studies have shown that HLA and SLA proteins share overlapping B cell epitopes due to structural or electrostatic similarities, but the role of overlapping T cell epitopes has not been fully explored. This study aims to computationally analyse the potential risk of memory T cell activation in subsequent human-after-swine and swine-after-human transplantation by evaluating shared T cell epitopes between the two graft sources. We show that while HLA and SLA demonstrate striking structural similarities, their linear protein sequences are very distinct, which translates to disparate HLA- and SLA-derived peptidomes and T cell epitopes. By applying the PIRCHE-II Tmem analysis to a simulated panel of recipients receiving repeat transplantations from a human kidney and from a swine xenograft, we observed a median of 1 shared T cell epitope in the cross-species context, compared to a median of 17 shared between two human-derived kidneys. This suggests that a swine xenograft exposes a low risk of T cell memory against a later human donor, and that xenotransplantation may provide an opportunity to receive a graft for highly HLA-sensitised recipients.
PMID: 40543909
ISSN: 2059-2310
CID: 5871482

Imlifidase in Kidney Transplantation: Balancing Safety and Practicality With the Promise of Expanding Access

Jaffe, Ian S; Lonze, Bonnie E; Montgomery, Robert A
PMID: 40320584
ISSN: 1534-6080
CID: 5838842

Documentation, Coding, and Billing for Neurologic Services and Procedures

Busis, Neil A; Montgomery, Robert; Cohen, Bruce H
Documentation, coding, and billing (claims submission) are foundational to neurologic practice in the United States, enabling accurate reimbursement, effective communication, and data-driven advancements in patient care, research, and education. Neurologists navigate complex regulatory frameworks and evolving payer guidelines, requiring meticulous attention to diagnostic coding, evaluation and management (E/M) services, and procedure-specific requirements. This chapter examines critical aspects of neurologic billing and coding, including ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) for diagnostic accuracy, updated E/M guidelines emphasizing medical decision-making and time, and new telemedicine codes. It highlights the best practices for procedure coding and the use of digital health technologies. The challenges posed by prior authorization are explored, alongside potential solutions like artificial intelligence-driven tools and policy reform. By prioritizing precision, compliance, and technological adaptation, neurologists can enhance patient outcomes, support practice sustainability, and contribute to the broader goals of equitable, efficient, and innovative neurologic care.
PMID: 40294605
ISSN: 1098-9021
CID: 5832122

Xenotransplantation: Current Understanding of the Mechanism of Immune Mediated Injury

Tatapudi, Vasishta S; Mattoo, Aprajita; Schiff, Tamar; Mehta, Sapna A; Skolnik, Edward Y; Montgomery, Robert A
The scarcity of transplantable organs represents a worldwide public health crisis, and as a result, thousands of people with end-stage kidney disease (ESKD) die waiting for a transplant each year. Xenotransplantation involves transplanting organs from an animal source into humans, offering a potential solution to this significant unmet need. Indeed, if there is a limitless supply of organs, many more patients who do not meet the current criteria for transplant eligibility could also be considered candidates. While there are examples of attempts to transplant animal tissues or organs into humans dating back over 300 years, none were successful due to cross-species immunologic incompatibility. Even so, significant advances in genetic engineering and the emergence of novel immunosuppressive agents have spurred impressive improvements in xenograft survival in preclinical studies involving nonhuman primates. Furthermore, recent reports of genetically modified pig kidney and heart xenotransplants in human decedents and living recipients on a compassionate use basis have provided impetus to advancing the field towards first-in-human trials. However, studies in nonhuman primates and humans thus far have described adaptive as well as innate immune-mediated xenograft injury. Understanding the mechanistic aspects of these responses at the cellular and molecular levels is critical to the development of targeted genetic modifications and innovative therapeutic strategies aimed at preventing rejection and inducing tolerance. Moreover, the physiological components of the bidirectional communication between the human host and pig xenograft must also be understood and manipulated. Here, we review the breakthroughs in renal xenotransplantation in the past few decades and highlight the immunologic hurdles that have yet to be overcome.
PMID: 40238253
ISSN: 1533-3450
CID: 5828222

Patient Selection for Xenotransplant Human Clinical Trials: A Data-driven Approach

Ata, Baris; Montgomery, Robert A; Ozyoruk, Yucel Naz; Parent, Brendan; Schold, Jesse D
PMID: 40164987
ISSN: 1534-6080
CID: 5818892

Transplantation in Ukraine

Montgomery, Robert A
PMID: 39298613
ISSN: 1534-6080
CID: 5721772

Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization

Jaffe, Ian S; Runström, Anna; Tatapudi, Vasishta S; Weldon, Elaina P; Deterville, Cecilia L; Dieter, Rebecca A; Montgomery, Robert A; Lonze, Bonnie E; Mangiola, Massimo
BACKGROUND/UNASSIGNED:Imlifidase is an IgG-cleaving endopeptidase conditionally approved in Europe for desensitization of highly sensitized patients before kidney transplantation. We present 5-y outcomes and donor-specific antibody (DSA) levels for clinical trial participants from a single site who received imlifidase for desensitization before incompatible transplantation (NCT02790437). METHODS/UNASSIGNED:Imlifidase was administered up to 24 h before living or deceased donor kidney transplantation. DSAs were monitored before transplantation, at days 7 and 28, and at 5 y posttransplant. RESULTS/UNASSIGNED:At 5 y, 7 of 8 participants were alive. One of these 7 had suboptimal graft function secondary to donor-derived disease but remained dialysis independent. Three participants had antibody-mediated rejection (AMR), which occurred in the first 30 d in all cases and was successfully treated. No new episodes of suspected or biopsy-proven AMR occurred after 30 d posttransplant. Seven participants had DSA rebound. DSAs commonly persisted 5 y posttransplant, although they were generally lower strength compared with pre-imlifidase. Dilution studies of sensitized serum enabled the identification of lower AMR risk phenotypes for persisting DSAs. Severe and/or opportunistic infections were not observed at greater than expected frequency. CONCLUSIONS/UNASSIGNED:Five-year outcomes of imlifidase-enabled incompatible transplants are overall favorable. DSA rebound is common, but antibody strength lessens in the long term, and longitudinally persisting DSAs did not lead to premature graft failure.
PMCID:11723687
PMID: 39802198
ISSN: 2373-8731
CID: 5776182

Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates

Torija, Alba; Matignon, Marie; Vincenti, Flavio; Casanova-Ferrer, Franc; Pilon, Caroline; Tambur, Anat R; Donadeu, Laura; Crespo, Elena; Kervella, Delphine; Meneghini, Maria; Torres, Irina B; Hafkamp, Florianne; Martinez-Lacalle, Anna; Carrera, Claudia; Zúñiga, José; Brar, Amarpali; Cruzado, Josep; Gaber, A Osama; Lee, Helen; Montgomery, Robert A; Stegall, Mark; Carmagnat, Maryvonnick; Usureau, Cédric; Moreso, Francesc; Grimbert, Philippe; Bestard, Oriol
High human leukocyte antigen (HLA) sensitization limits access to compatible transplantation. New CD38-targeting agents have been shown to reduce anti-HLA antibodies, although with important interpatient variability. Thus, pretreatment identification of responder and nonresponder (NR) patients is needed for treatment decision-making. We analyzed 26 highly sensitized (HS) patients from 2 desensitization trials using anti-CD38 monoclonal antibodies. Hierarchical clustering identified 3 serologic responder groups: high responders, low responders, and NR. Spectral flow cytometry and functional HLA-specific memory B cell (mBC) assessment were first conducted on peripheral blood mononuclear cells and bone marrow samples from 16 patients treated with isatuximab (NCT04294459). Isatuximab effectively depleted bone marrow plasma cells, peripheral CD38-expressing plasmablasts, plasma cells, transitional B cells, and class-switch mBCs, ultimately reducing frequencies of HLA-specific immunoglobulin G (IgG)-producing mBCs. Multidimensional spectral flow cytometry with partial least squares discriminant analysis revealed that pretreatment abundance of specific circulating mBC phenotypes, especially CD38neg class-switch mBCs, accurately distinguished between high serologic responders and low responders or NR (AUC 0.958, 0.860-1.000, P = .009), who also displayed significantly lower frequencies of HLA-specific IgG-producing mBCs (P < .0001). This phenotypical mBC signature predicting response to therapy was validated in an external HS patient cohort (n = 10) receiving daratumumab (NCT04204980). This study identifies critical circulating mBC subset phenotypes that distinguish HS patients with successful serologic responses to CD38-targeting desensitization therapies, potentially guiding treatment decision-making.
PMID: 39134120
ISSN: 1600-6143
CID: 5726772

Mapping the Evolution of Solid Organ Xenotransplantation Research:A Systematic Review

Juric, Ivana; Raynaud, Marc; Skoric, Lea; Al-Awadhi, Solaf; Truchot, Agathe; Sablik, Marta; Ma, Xiaoqian; Lv, Kaikai; Zhang, Huanxi; Louis, Kevin; Basic-Jukic, Nikolina; Tissier, Renaud; Hauet, Thierry; Cozzi, Emanuele; Oniscu, Gabriel C; Mangiola, Massimo; Tector, Joseph A; Riella, Leonardo V; Locke, Jayme E; Samuel, Didier; Meier, Raphael P H; Mohiuddin, Muhammad M; Montgomery, Robert A; Loupy, Alexandre
INTRODUCTION:Xenotransplantation has emerged as a promising solution to organ shortage, generating numerous publications. However, no studies have analyzed the research dynamics of xenotransplantation research. We aimed to systematically assess xenotransplantation publication activity. METHODS:A systematic literature search was conducted up to November 22, 2024. Studies on xenotransplantation of solid organs and islets of Langerhans from animals to humans, or perfusion with human blood or its derivatives were included. Publication information, publishing journal, publication type, organ, donor species, and topics studied were extracted. RESULTS:Of 2944 publications, 706 met inclusion criteria: 41.2% original articles, 41.1% reviews, 14.2% publications without original data, 1.6% case reports, 1.3% research letters, 0.6% systematic reviews/meta-analyses. Publication activity displayed two peaks: in the 1990s, driven by the gene editing advancements, and in the early 2020s, following the first pig-to-human transplantation. The top five publishing countries were the USA with (48.2%), Germany (10.2%), UK (5.4%), Sweden (4.8%), and China (4.2%). Xenotransplantation journal accounted for 19.7% of publications, transplantation journals for 27.6%, and general medical journals for 5.4%. Islets of Langerhans were studied in 23.1% of studies, and the most studied organs were heart (21.2%), followed by kidney (17.1%), liver (12.2%), and lung (6.2%). The most represented thematic groups were rejection, immune mechanisms, overall challenges, gene editing, current research, and prospects. CONCLUSION:This first systematic assessment of xenotransplantation research highlights its growing global interest and evolving focus areas. The low proportion of publications with original data underscores the need for more original research. Limited representation in general medical journals highlights the importance of engaging a broader audience as clinical trials approach.
PMID: 40551623
ISSN: 1399-3089
CID: 5874672

Long-term outcomes at 5 years posttransplant in imlifidase-desensitized kidney transplant patients [Letter]

Jordan, Stanley C; Maldonado, Angela Q; Lonze, Bonnie E; Sjöholm, Kristoffer; Lagergren, Anna; Montgomery, Robert A; Runström, Anna; Desai, Niraj M; Legendre, Christophe; Lundgren, Torbjörn; von Zur Mühlen, Bengt; Vo, Ashley A; Tollemar, Jan; Lefèvre, Paola; Lorant, Tomas
PMID: 39643005
ISSN: 1600-6143
CID: 5804642